Limits...
Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphoma.

Toda H, Sato Y, Takata K, Orita Y, Asano N, Yoshino T - PLoS ONE (2013)

Bottom Line: According to both Hans' and Choi's algorithms, the non-GCB type was predominant.Nevertheless, prognosis was good.In conclusion, although the non-GCB subtype is thought to show poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of subclassification.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) comprises 2 molecularly distinct subgroups of non-germinal center B-cell-like (non-GCB) and germinal center B-cell-like (GCB) DLBCLs, with the former showing relatively poor prognosis. In the present study, we analyzed the clinicopathological features of 39 patients with localized nasal/paranasal DLBCL. Immunohistochemistry-based subclassification revealed that 11 patients (28%) were of the GCB-type according to Hans' algorithm and 11 (28%) were of the GCB-type according to Choi's algorithm. According to both Hans' and Choi's algorithms, the non-GCB type was predominant. Nevertheless, prognosis was good. Overall survival did not differ significantly between the GCB and non-GCB subgroups (Hans' algorithm: p = 0.57, Choi's algorithm: p = 0.99). Furthermore, the prognosis of localized nasal/paranasal DLBCL was better than that of other localized extranodal DLBCLs. The prognosis of extranodal DLBCL is usually considered poorer than that of nodal DLBCL. However, in our study, no difference was noted between patients with localized nasal/paranasal DLBCL and patients with localized nodal DLBCL. In conclusion, although the non-GCB subtype is thought to show poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of subclassification.

Show MeSH

Related in: MedlinePlus

Comparison of overall survival between localized nasal/paranasal DLBCL and localized nodal DLBCL.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585191&req=5

pone-0057677-g004: Comparison of overall survival between localized nasal/paranasal DLBCL and localized nodal DLBCL.

Mentions: The clinicopathological characteristics of nasal/paranasal DLBCL and localized nodal DLBCL are summarized in Table 5. Nasal/paranasal DLBCL patients showed good prognosis. The slight difference in the overall survival between these patients and patients with localized nodal DLBCL was not significant (p = 0.30) (Fig. 4). Moreover, analysis using the χ2-test revealed a significant difference between the 2 groups with regard to age distribution and immunophenotype. Localized nasal/paranasal DLBCL patients were more likely to be more than 60 years old than localized nodal DLBCL patients (p = 0.018). In addition, localized nasal/paranasal DLBCL patients showed significantly higher positivity for MUM1 than localized nodal DLBCL patients according to Choi’s algorithm (p = 0.00023, χ2-test).


Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphoma.

Toda H, Sato Y, Takata K, Orita Y, Asano N, Yoshino T - PLoS ONE (2013)

Comparison of overall survival between localized nasal/paranasal DLBCL and localized nodal DLBCL.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585191&req=5

pone-0057677-g004: Comparison of overall survival between localized nasal/paranasal DLBCL and localized nodal DLBCL.
Mentions: The clinicopathological characteristics of nasal/paranasal DLBCL and localized nodal DLBCL are summarized in Table 5. Nasal/paranasal DLBCL patients showed good prognosis. The slight difference in the overall survival between these patients and patients with localized nodal DLBCL was not significant (p = 0.30) (Fig. 4). Moreover, analysis using the χ2-test revealed a significant difference between the 2 groups with regard to age distribution and immunophenotype. Localized nasal/paranasal DLBCL patients were more likely to be more than 60 years old than localized nodal DLBCL patients (p = 0.018). In addition, localized nasal/paranasal DLBCL patients showed significantly higher positivity for MUM1 than localized nodal DLBCL patients according to Choi’s algorithm (p = 0.00023, χ2-test).

Bottom Line: According to both Hans' and Choi's algorithms, the non-GCB type was predominant.Nevertheless, prognosis was good.In conclusion, although the non-GCB subtype is thought to show poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of subclassification.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) comprises 2 molecularly distinct subgroups of non-germinal center B-cell-like (non-GCB) and germinal center B-cell-like (GCB) DLBCLs, with the former showing relatively poor prognosis. In the present study, we analyzed the clinicopathological features of 39 patients with localized nasal/paranasal DLBCL. Immunohistochemistry-based subclassification revealed that 11 patients (28%) were of the GCB-type according to Hans' algorithm and 11 (28%) were of the GCB-type according to Choi's algorithm. According to both Hans' and Choi's algorithms, the non-GCB type was predominant. Nevertheless, prognosis was good. Overall survival did not differ significantly between the GCB and non-GCB subgroups (Hans' algorithm: p = 0.57, Choi's algorithm: p = 0.99). Furthermore, the prognosis of localized nasal/paranasal DLBCL was better than that of other localized extranodal DLBCLs. The prognosis of extranodal DLBCL is usually considered poorer than that of nodal DLBCL. However, in our study, no difference was noted between patients with localized nasal/paranasal DLBCL and patients with localized nodal DLBCL. In conclusion, although the non-GCB subtype is thought to show poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of subclassification.

Show MeSH
Related in: MedlinePlus